AKT1 and breast cancer: For instance, Huw et al. reported that breast cancer cells with PIK3CA amplification or mutations exhibited resistance to a PI3Kα/δ inhibitor, pictilisib, due to the high amplification of the mutant PIK3CA exon 20 p.H1047R locus, leading to increased AKT phosphorylation [25].